Affiliation: University of Chicago
- A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myelomaAndrzej J Jakubowiak
University of Chicago Medical Center, Chicago, IL 60637 6613, USA
Blood 120:1801-9. 2012..CRd was well tolerated with exceptional response rates. This study is registered at http://www.clinicaltrials.gov as NCT01029054...
- Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium studyAndrzej J Jakubowiak
University of Michigan Cancer Center, Ann Arbor, MI, USA
Br J Haematol 158:472-80. 2012..Response was associated with phospho-Akt in pharmacodynamic studies. Perifosine-lenalidomide-dexamethasone was well tolerated and demonstrated encouraging clinical activity in relapsed and relapsed/refractory MM...
- Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed/refractory multiple myelomaAndrzej J Jakubowiak
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA
J Clin Oncol 30:1960-5. 2012..To evaluate the maximum-tolerated dose (MTD), safety, and efficacy of elotuzumab in combination with bortezomib in patients with relapsed or relapsed and refractory multiple myeloma (MM)...
- Management strategies for relapsed/refractory multiple myeloma: current clinical perspectivesAndrzej Jakubowiak
University of Chicago Medical Center, Chicago, IL 60637, USA
Semin Hematol 49:S16-32. 2012....